Navigation Links
Amgen's Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To $1.29
Date:7/27/2009

p>
        Cost of sales increased 3 percent to $527 million in the second
        quarter of 2009 versus $512 million in the second quarter of 2008
        primarily driven by higher fill and finish costs resulting from lower
        utilization at our manufacturing facility in Puerto Rico.

        Research & Development (R&D) expenses were $657 million in the second
        quarter of 2009 versus $779 million in the second quarter of 2008, a
        decrease of 16 percent.  This decrease is in part due to the $100
        million expense in the second quarter of 2008 resulting from the
        upfront payment associated with the Kyowa Hakko collaboration.  The
        remainder of the expense decrease was primarily driven by lower
        clinical trial costs for denosumab and Vectibix registrational
        studies, partially offset by a $50 million expense in the second
        quarter of 2009 resulting from the payment to obtain an exclusive
        license to Cytokinetics' cardiac contractility program.

        Selling, General & Administrative (SG&A) expenses were relatively
        unchanged at $891 million in the second quarter of 2009 versus $894
        million in the prior year.  Lower staff related expenses, lower
        litigation expenses, and lower enterprise resource planning (ERP)
        system related expenses were offset by higher promotional expenses for
        marketed products, increased spending for activities in preparation
        and anticipation of approval and launch of denosumab, and higher
        expenses associated with the Wyeth profit share due to higher ENBREL
        sales.

        Excluding expenses associated with the Wyeth profit share of $301
        million and $283 million in the second quarter of 2009 and 2008,
        respectively, adjusted SG&A expenses in the second quarter of 2009
        decreased 3 percent versus the same quarter last year.


'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Related medicine news :

1. Burgeoning Population of Hepatitis C Virus Patients in Need of Second- and Third-Line Treatment Options
2. Medical Services International Maintains Pace in Second Quarter
3. CEOs Need an Advertising Check Up or Second Opinion
4. Trojan(R) Ranks U.S. Colleges and Universities in Second Annual Sexual Health Report Card
5. HealthMedia Revolution Explodes in Second Quarter
6. J.D. Power and Associates Reports: CIGNA HealthCare Recognized for Call Center Customer Satisfaction Excellence For a Second Consecutive Year
7. Acting Surgeon General Announces National Initiatives to Protect Children by Reducing Exposure to Secondhand Smoke
8. Roller Derby Author Cheats Death a Second Time
9. Launch of second European Cancer Research Funding survey
10. Secondhand smoke increases teen test failure
11. Elder Care Author Doctor Marion Launches Second National Tour to Raise Awareness About Aging & Elder Care Issues in America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... a very familiar "lub-dub" pattern that speeds up or ... pattern itself isn,t as regular as you might think. ... vary even at a "constant" heart rateand that variability, ... Reduced heart rate variability (HRV) has been found to ... congestive heart failure and inflammation. For athletes, a drop ...
(Date:9/22/2014)... 22, 2014 WHO: LiveOps, Inc., ... customer service solutions. , WHAT: The 10th annual ... customer care for the connected consumer. Constant change ... offer new challenges and opportunities for customer experience ... identify best practices, network and learn from fellow ...
(Date:9/22/2014)... By Tara Haelle ... (HealthDay News) -- Measuring how quickly a child,s brain ... according to a new study. Observing children,s ... is currently possible, the study authors reported. "The ... information is associated with autism severity is hugely promising," ...
(Date:9/22/2014)... CA (PRWEB) September 22, 2014 ... California for a three-day conference to discuss brain-related ... brain injury from concussions and neurodegenerative disorders. ... medical director affiliated with a Silverado memory care ... of dedicated expertise in memory care, hosts the ...
(Date:9/22/2014)... September 22, 2014 The report ... application, end user, and geography. The equipment segment ... physiotherapy equipment market, by product. However, the accessories ... CAGR in the forecast period, owing to the ... Electric stimulation and ultrasound segments are the fastest-growing ...
Breaking Medicine News(10 mins):Health News:Variability keeps the body in balance 2Health News:Variability keeps the body in balance 3Health News:Variability keeps the body in balance 4Health News:LiveOps To Lead Panel Discussion At Customer Response Summit Memphis 2Health News:Brainwaves May Help Gauge Autism Severity: Study 2Health News:Brainwaves May Help Gauge Autism Severity: Study 3Health News:Brainwaves May Help Gauge Autism Severity: Study 4Health News:Nation’s Leading Brain Health Experts Gather for Annual Silverado Medical Director Conference 2Health News:Nation’s Leading Brain Health Experts Gather for Annual Silverado Medical Director Conference 3Health News:6.8% CAGR for Physiotherapy Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 2Health News:6.8% CAGR for Physiotherapy Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 3Health News:6.8% CAGR for Physiotherapy Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 4Health News:6.8% CAGR for Physiotherapy Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 5
... 5.6 Onboard Software to Navigate the Safest, Most Fuel-Efficient Route and Protect ... the World,s Poor , ... Sunnyvale, Calif. (Vocus) March 16, 2009 -- ... , the leader in using hospital ships to deliver free, world-class health ...
... making great money is a reality. This year we focus on advancing ... Social Engineering. Spring ChicagoCon 2009 by TDCC features world-class security training followed ... career on the cutting edge of technology and the human mind. ... ...
... harm that often follows brain injury, researcher says, , , ... of Alzheimer,s disease drugs may prevent long-term damage from ... Georgetown University Medical Center researchers. , The drugs -- ... that accumulates in the brains of people with Alzheimer,s ...
... getaway destinations are affected, studies find , , SUNDAY, March 15 ... can be a burden on a family,s finances and even ... be presented in Washington, D.C., at the annual meeting of ... these common conditions can have a wide impact on a ...
... All-In-One Mobility Solutions , ... Blue ... proud to announce the branding of RACO,s Advanced Solutions Group ... area network design, RFID compliance and application software development services ...
... WILMINGTON, Del., March 14 Today AstraZeneca ... in response to the appointment of a new FDA ... Commissioner of the Food and Drug Administration. Dr. Hamburg ... will serve the agency well in these challenging times. ...
Cached Medicine News:Health News:Applied Weather Technology Guides Mercy Ships with Latest BVS Marine Voyage Optimization Software 2Health News:Applied Weather Technology Guides Mercy Ships with Latest BVS Marine Voyage Optimization Software 3Health News:Applied Weather Technology Guides Mercy Ships with Latest BVS Marine Voyage Optimization Software 4Health News:Applied Weather Technology Guides Mercy Ships with Latest BVS Marine Voyage Optimization Software 5Health News:Chicago's Own Hacker Con Set for May, Teaches Human Hacking to Corporations 2Health News:Chicago's Own Hacker Con Set for May, Teaches Human Hacking to Corporations 3Health News:Alzheimer's Drug May Someday Help Head Trauma Victims 2Health News:Child's Food Allergies Take Toll on Family Plans 2Health News:RACO Brands Its Advanced Solutions Group 2Health News:AstraZeneca Applauds Appointment of New FDA Commissioner 2
(Date:9/22/2014)... Sept. 22, 2014  AbbVie (NYSE: ... studies evaluating potential new medicines in the company,s ... 2014 European Society of Medical Oncology (ESMO) Annual ... . Data being presented include results from ... efficacy of veliparib (ABT-888), a poly (adenosine diphosphate ...
(Date:9/22/2014)... BRIDGEWATER, N.J. , Sept. 22, 2014 /PRNewswire/ ... focused on developing and commercializing therapeutic products for ... disease, today is pleased to announce that TUV-SUD ... the Netherlands (MEB) has granted its ... catheter lock solution.  Neutrolin was initially approved in ...
(Date:9/22/2014)... NEW YORK , Sept. 22, ... has signed an exclusive, global license agreement with ... commercialization of its proprietary plasma fractionation process. Concurrently, ... and its intention to strategically refocus and rebrand ... plans to pursue a national listing for its ...
Breaking Medicine Technology:AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 2AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 3AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 4Neutrolin Label Expansion Approved for the European Union 2Neutrolin Label Expansion Approved for the European Union 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 2Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 4Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 5Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 6
... 2011 Nektar Therapeutics (Nasdaq: NKTR ) today reported ... Cash, cash equivalents, and investments at September 30, ... 31, 2010. Revenue for the third quarter of ... in the third quarter of 2010 primarily as a result of ...
... NEW YORK, Nov. 2, 2011 JDRF and The Leona ... largest non-government funders of type 1 diabetes (T1D) programs, announced ... a new level of cooperation between the organizations. The goal ... and development to deliver better treatments, devices, and diagnostics for ...
Cached Medicine Technology:Nektar Therapeutics Reports Third Quarter 2011 Financial Results 2Nektar Therapeutics Reports Third Quarter 2011 Financial Results 3Nektar Therapeutics Reports Third Quarter 2011 Financial Results 4Nektar Therapeutics Reports Third Quarter 2011 Financial Results 5Nektar Therapeutics Reports Third Quarter 2011 Financial Results 6Nektar Therapeutics Reports Third Quarter 2011 Financial Results 7Nektar Therapeutics Reports Third Quarter 2011 Financial Results 8JDRF and the Helmsley Charitable Trust Form a Collaboration to Accelerate Innovative Type 1 Diabetes Research and Development 2JDRF and the Helmsley Charitable Trust Form a Collaboration to Accelerate Innovative Type 1 Diabetes Research and Development 3JDRF and the Helmsley Charitable Trust Form a Collaboration to Accelerate Innovative Type 1 Diabetes Research and Development 4
... Western Blot Kits provide a sensitive and ... Borrelia burgdorferi. Proteins from the spirochete are ... antigens are fractionated according to molecular weight ... in the presence of sodium dodecyl sulfate. ...
Surgitie&trade Single Use Ligating Loops with Delivery System...
Surgitie&trade Single Use Ligating Loops with Delivery System...
ENDO STITCH™ Single Use Loading Units....
Medicine Products: